Abstract
During evolution, pathogens have evolved strategies to counteract key cellular restriction mechanisms in order to efficiently invade target cells and fulfill essential steps of their replication cycle. Human Immunodeficiency Virus-1 and some Simian counterparts express a small multifunctional protein, Vpu, which influences viral replication. By acting as a multifunctional adapter, Vpu enhances viral particle release and infectivity. Therefore Vpu, an accessory protein, contributes to pathogenesis while avoiding superinfection. These effects rely mainly on the ability of Vpu to target the host proteins CD4 and BST-2/tetherin. Indeed, Vpu downregulates the cell surface expression of these receptors and subsequently induces their proteolysis via a mechanism involving a β -TrCP-containing E3 ubiquitin ligase complex. In this review, we will detail recent research aimed at elucidating the mechanism of Vpu-mediated CD4 and BST-2/tetherin downregulation and degradation as well as their subsequent consequences on viral pathogenesis.
Keywords: BST-2/tetherin, CD4, Human Immunodeficiency Virus-1 (HIV-1), lysosome, proteasome, SCFbTrCP E3 ubiquitin ligase, Ubiquitination, Viral Protein U (Vpu), degradation, proteolysis
Current HIV Research
Title:β -TrCP Dependency of HIV-1 Vpu-Induced Downregulation of CD4 and BST-2/Tetherin
Volume: 10 Issue: 4
Author(s): Fabien P. Blanchet, J. P. Mitchell and Vincent Piguet
Affiliation:
Keywords: BST-2/tetherin, CD4, Human Immunodeficiency Virus-1 (HIV-1), lysosome, proteasome, SCFbTrCP E3 ubiquitin ligase, Ubiquitination, Viral Protein U (Vpu), degradation, proteolysis
Abstract: During evolution, pathogens have evolved strategies to counteract key cellular restriction mechanisms in order to efficiently invade target cells and fulfill essential steps of their replication cycle. Human Immunodeficiency Virus-1 and some Simian counterparts express a small multifunctional protein, Vpu, which influences viral replication. By acting as a multifunctional adapter, Vpu enhances viral particle release and infectivity. Therefore Vpu, an accessory protein, contributes to pathogenesis while avoiding superinfection. These effects rely mainly on the ability of Vpu to target the host proteins CD4 and BST-2/tetherin. Indeed, Vpu downregulates the cell surface expression of these receptors and subsequently induces their proteolysis via a mechanism involving a β -TrCP-containing E3 ubiquitin ligase complex. In this review, we will detail recent research aimed at elucidating the mechanism of Vpu-mediated CD4 and BST-2/tetherin downregulation and degradation as well as their subsequent consequences on viral pathogenesis.
Export Options
About this article
Cite this article as:
P. Blanchet Fabien, P. Mitchell J. and Piguet Vincent, β -TrCP Dependency of HIV-1 Vpu-Induced Downregulation of CD4 and BST-2/Tetherin, Current HIV Research 2012; 10 (4) . https://dx.doi.org/10.2174/157016212800792441
DOI https://dx.doi.org/10.2174/157016212800792441 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Knocking Down Gene Expression with Dendritic Vectors
Mini-Reviews in Medicinal Chemistry Matrix Metalloproteinases as Valid Clinical Target
Current Pharmaceutical Design The Selective Packaging and Annealing of Primer tRNALys3 in HIV-1
Current HIV Research The Chemical Biology of Immunophilin Ligands
Current Medicinal Chemistry Review of Current Chemoinformatic Tools for Modeling Important Aspects of CYPsmediated Drug Metabolism. Integrating Metabolism Data with Other Biological Profiles to Enhance Drug Discovery
Current Drug Metabolism Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety Optimizing Gene Silencing Strategies for Pancreatic Cancer
Current Cancer Therapy Reviews Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives
Current Medicinal Chemistry Arsenic Trioxide Exerts Anti-lung Cancer Activity by Inhibiting Angiogenesis
Current Cancer Drug Targets Anal Cancer: Focus on HIV-Positive Patients in the HAART Era
Current HIV Research Discovery of Novel Plant Peptides as Strong Inhibitors of Metalloproteinases
Protein & Peptide Letters DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design Stem Cells in Brain Tumorigenesis and their Impact on Therapy
Current Stem Cell Research & Therapy Radiosynthesis of [18F]-fluorobenzoate-doxorubicin Using Acylation Approach
Current Radiopharmaceuticals Recent Advances in pH-Sensitive Polymeric Nanoparticles for Smart Drug Delivery in Cancer Therapy
Current Drug Targets Interferon Treatment in Patients with Hypereosinophilia
Current Drug Targets PEGylated Liposomal Vancomycin: A Glimmer of Hope for Improving Treatment Outcomes in MRSA Pneumonia
Recent Patents on Anti-Infective Drug Discovery p53: An Attractive Therapeutic Target for Cancer
Current Medicinal Chemistry Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy
Current Drug Targets NK Cell Function in HIV-1 Infection
Current HIV Research